You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNilvadipine
Accession NumberDB06712
TypeSmall Molecule
GroupsApproved
DescriptionNilvadipine is a calcium channel blocker (CCB) for treatment of hypertension.
Structure
Thumb
Synonyms
Nivadil
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NivadilNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0214FUT37J
CAS number75530-68-6
WeightAverage: 385.3707
Monoisotopic: 385.127385355
Chemical FormulaC19H19N3O6
InChI KeyFAIIFDPAEUKBEP-UHFFFAOYSA-N
InChI
InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
IUPAC Name
3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
Pharmacology
IndicationFor the management of vasospastic angina, chronic stable angina and hypertension.
Structured Indications Not Available
PharmacodynamicsNilvadipine is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. Nilvadipine is used to treat Prinzmetal's angina, hypertension, and other vascular disorders such as Raynaud's phenomenon. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.
Mechanism of actionNilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent calcium channel subunit alpha-2/delta-1Proteinyes
inhibitor
HumanP54289 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinunknown
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinunknown
inhibitor
HumanQ13698 details
Voltage-dependent calcium channel subunit alpha-2/delta-3Proteinunknown
inhibitor
HumanQ8IZS8 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nilvadipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nilvadipine.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nilvadipine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Nilvadipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nilvadipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
AliskirenNilvadipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Nilvadipine.Approved, Withdrawn
AmbrisentanNilvadipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNilvadipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nilvadipine.Approved
AmiodaroneThe metabolism of Nilvadipine can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Nilvadipine.Approved
AmobarbitalThe metabolism of Nilvadipine can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nilvadipine.Approved
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nilvadipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nilvadipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Nilvadipine.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nilvadipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nilvadipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nilvadipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nilvadipine.Approved
AprepitantThe serum concentration of Nilvadipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nilvadipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nilvadipine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nilvadipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nilvadipine.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nilvadipine resulting in a loss in efficacy.Approved
AtazanavirThe metabolism of Nilvadipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Nilvadipine.Approved
AtomoxetineThe metabolism of Nilvadipine can be decreased when combined with Atomoxetine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Atosiban.Approved
Atracurium besylateNilvadipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nilvadipine.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nilvadipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nilvadipine.Experimental
BarbitalThe metabolism of Nilvadipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nilvadipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nilvadipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nilvadipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nilvadipine.Approved
BepridilBepridil may increase the hypotensive activities of Nilvadipine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Nilvadipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Nilvadipine.Approved
BexaroteneThe serum concentration of Nilvadipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nilvadipine.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Nilvadipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Nilvadipine.Approved
BoceprevirThe metabolism of Nilvadipine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Nilvadipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nilvadipine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Nilvadipine.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Nilvadipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nilvadipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nilvadipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Nilvadipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nilvadipine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nilvadipine.Approved, Investigational
BupranololNilvadipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nilvadipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nilvadipine.Approved
CalciumThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Nilvadipine.Approved
CandesartanCandesartan may increase the hypotensive activities of Nilvadipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nilvadipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Nilvadipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Nilvadipine.Approved
CarbamazepineThe metabolism of Nilvadipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nilvadipine.Approved
CarbomycinThe metabolism of Nilvadipine can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nilvadipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Nilvadipine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nilvadipine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
CeritinibThe serum concentration of Nilvadipine can be increased when it is combined with Ceritinib.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nilvadipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nilvadipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nilvadipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nilvadipine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nilvadipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nilvadipine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Nilvadipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nilvadipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nilvadipine.Approved
CimetidineThe serum concentration of Nilvadipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Nilvadipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nilvadipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nilvadipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nilvadipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nilvadipine.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Nilvadipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nilvadipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nilvadipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nilvadipine.Approved
CobicistatThe metabolism of Nilvadipine can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Nilvadipine can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nilvadipine.Investigational
CrizotinibThe metabolism of Nilvadipine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nilvadipine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nilvadipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nilvadipine.Approved
Cyproterone acetateThe serum concentration of Nilvadipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Nilvadipine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Nilvadipine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nilvadipine.Investigational
DarunavirThe metabolism of Nilvadipine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Nilvadipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Nilvadipine.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nilvadipine.Experimental
DeferasiroxThe serum concentration of Nilvadipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nilvadipine can be decreased when combined with Delavirdine.Approved
DeserpidineNilvadipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nilvadipine.Approved
DexamethasoneThe serum concentration of Nilvadipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nilvadipine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nilvadipine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nilvadipine.Approved
DihydralazineNilvadipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Nilvadipine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Nilvadipine can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nilvadipine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nilvadipine.Approved
DisulfiramThe metabolism of Nilvadipine can be decreased when combined with Disulfiram.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nilvadipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Nilvadipine.Approved
DoxycyclineThe metabolism of Nilvadipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Nilvadipine can be decreased when combined with Dronedarone.Approved
DuloxetineNilvadipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nilvadipine.Approved
EfavirenzThe serum concentration of Nilvadipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nilvadipine.Approved
EfonidipineNilvadipine may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nilvadipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Nilvadipine.Approved, Vet Approved
EnalaprilatNilvadipine may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Nilvadipine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nilvadipine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Nilvadipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Nilvadipine.Approved
ErythromycinThe metabolism of Nilvadipine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Nilvadipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nilvadipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nilvadipine.Approved
EtravirineThe serum concentration of Nilvadipine can be decreased when it is combined with Etravirine.Approved
FelodipineFelodipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Nilvadipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nilvadipine.Approved
FluconazoleThe serum concentration of Nilvadipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nilvadipine.Approved
FluvoxamineThe metabolism of Nilvadipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nilvadipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nilvadipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Nilvadipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nilvadipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nilvadipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nilvadipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nilvadipine can be increased when it is combined with Fusidic Acid.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nilvadipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nilvadipine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Nilvadipine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nilvadipine.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Nilvadipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nilvadipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nilvadipine.Approved, Vet Approved
HexamethoniumNilvadipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nilvadipine.Approved
HexobarbitalThe metabolism of Nilvadipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nilvadipine.Approved
HydralazineHydralazine may increase the hypotensive activities of Nilvadipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nilvadipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nilvadipine.Approved
IdelalisibThe serum concentration of Nilvadipine can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Nilvadipine.Approved, Investigational
ImatinibThe metabolism of Nilvadipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nilvadipine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nilvadipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Nilvadipine.Approved
IndenololNilvadipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nilvadipine can be decreased when combined with Indinavir.Approved
IndoraminNilvadipine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nilvadipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nilvadipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nilvadipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nilvadipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nilvadipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nilvadipine.Approved, Vet Approved
IsoniazidThe metabolism of Nilvadipine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nilvadipine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nilvadipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Nilvadipine.Approved, Withdrawn
IsradipineThe metabolism of Nilvadipine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Nilvadipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nilvadipine can be increased when it is combined with Ivacaftor.Approved
JosamycinThe metabolism of Nilvadipine can be decreased when combined with Josamycin.Approved
KetanserinNilvadipine may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Nilvadipine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Nilvadipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Nilvadipine.Approved
LacidipineNilvadipine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Nilvadipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nilvadipine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nilvadipine.Approved
LevodopaNilvadipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nilvadipine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
LopinavirThe metabolism of Nilvadipine can be decreased when combined with Lopinavir.Approved
LosartanLosartan may increase the hypotensive activities of Nilvadipine.Approved
LovastatinThe metabolism of Nilvadipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nilvadipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nilvadipine can be increased when combined with Lumacaftor.Approved
MacitentanNilvadipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineNilvadipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nilvadipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nilvadipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Nilvadipine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nilvadipine.Approved
MethohexitalThe metabolism of Nilvadipine can be increased when combined with Methohexital.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nilvadipine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Nilvadipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nilvadipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nilvadipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Nilvadipine can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Nilvadipine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Nilvadipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
MetyrosineNilvadipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nilvadipine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Nilvadipine.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nilvadipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nilvadipine.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Nilvadipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nilvadipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Nilvadipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Nilvadipine.Approved
MitotaneThe serum concentration of Nilvadipine can be decreased when it is combined with Mitotane.Approved
MivacuriumNilvadipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nilvadipine.Approved
ModafinilThe serum concentration of Nilvadipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Nilvadipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nilvadipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nilvadipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nilvadipine.Approved, Investigational
MoxonidineNilvadipine may increase the hypotensive activities of Moxonidine.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nilvadipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nilvadipine.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Nilvadipine.Approved
NafcillinThe metabolism of Nilvadipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nilvadipine.Approved
NaftopidilNilvadipine may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nilvadipine.Approved
NebivololNebivolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NefazodoneThe metabolism of Nilvadipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nilvadipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Nilvadipine.Approved, Investigational
NetupitantThe serum concentration of Nilvadipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Nilvadipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nilvadipine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Nilvadipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Nilvadipine.Approved
NicotineThe metabolism of Nilvadipine can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nilvadipine.Approved
NiguldipineNilvadipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Nilvadipine can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Nilvadipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Nilvadipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Nilvadipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nilvadipine.Approved, Investigational
NitroprussideNilvadipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nilvadipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nilvadipine.Approved, Vet Approved
ObinutuzumabNilvadipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nilvadipine.Withdrawn
OlaparibThe metabolism of Nilvadipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Nilvadipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Nilvadipine.Investigational
OsimertinibThe serum concentration of Nilvadipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nilvadipine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Nilvadipine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nilvadipine.Investigational
PalbociclibThe serum concentration of Nilvadipine can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nilvadipine.Approved
PargylinePargyline may increase the hypotensive activities of Nilvadipine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nilvadipine.Approved
PentobarbitalThe metabolism of Nilvadipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Nilvadipine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nilvadipine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Nilvadipine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nilvadipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nilvadipine.Withdrawn
PhenobarbitalThe metabolism of Nilvadipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nilvadipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nilvadipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nilvadipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nilvadipine.Approved, Vet Approved
PinacidilNilvadipine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPindolol may increase the hypotensive activities of Nilvadipine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Nilvadipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nilvadipine.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Nilvadipine.Approved
PosaconazoleThe metabolism of Nilvadipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the hypotensive activities of Nilvadipine.Approved
PrimidoneThe metabolism of Nilvadipine can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nilvadipine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Nilvadipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nilvadipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Nilvadipine.Approved
RanolazineThe metabolism of Nilvadipine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumNilvadipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nilvadipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nilvadipine.Approved
RescinnamineNilvadipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Nilvadipine.Approved
RifabutinThe metabolism of Nilvadipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Nilvadipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Nilvadipine can be increased when combined with Rifapentine.Approved
RilmenidineNilvadipine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatNilvadipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneNilvadipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Nilvadipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabNilvadipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nilvadipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nilvadipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nilvadipine.Approved, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Nilvadipine.Experimental
SaquinavirThe metabolism of Nilvadipine can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Nilvadipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nilvadipine.Approved, Investigational, Vet Approved
SelexipagNilvadipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nilvadipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nilvadipine.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Nilvadipine.Approved
SiltuximabThe serum concentration of Nilvadipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nilvadipine can be increased when it is combined with Simeprevir.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nilvadipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nilvadipine.Approved, Investigational
SitaxentanNilvadipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sodium Nitrite.Approved
SolithromycinThe metabolism of Nilvadipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nilvadipine.Approved
SpiraprilSpirapril may increase the hypotensive activities of Nilvadipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nilvadipine.Approved
St. John's WortThe serum concentration of Nilvadipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Nilvadipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nilvadipine.Approved
SulfisoxazoleThe metabolism of Nilvadipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the antihypertensive activities of Nilvadipine.Approved, Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nilvadipine.Approved
TelaprevirThe metabolism of Nilvadipine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Nilvadipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
TemocaprilNilvadipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Nilvadipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nilvadipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nilvadipine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Nilvadipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nilvadipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Thioridazine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nilvadipine.Approved
TiboloneNilvadipine may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Nilvadipine can be decreased when combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Nilvadipine.Withdrawn
TimololTimolol may increase the hypotensive activities of Nilvadipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nilvadipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nilvadipine.Approved
TocilizumabThe serum concentration of Nilvadipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Nilvadipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nilvadipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Nilvadipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Nilvadipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Nilvadipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nilvadipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nilvadipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nilvadipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nilvadipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nilvadipine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nilvadipine.Approved, Vet Approved
TrimazosinNilvadipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nilvadipine.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nilvadipine.Approved, Investigational
TroleandomycinThe metabolism of Nilvadipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Nilvadipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Nilvadipine.Approved, Investigational
UnoprostoneNilvadipine may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nilvadipine.Approved
VenlafaxineThe metabolism of Nilvadipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Nilvadipine can be decreased when combined with Verapamil.Approved
VinpocetineNilvadipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Nilvadipine can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineXylometazoline may increase the hypotensive activities of Nilvadipine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nilvadipine.Approved, Vet Approved
ZiprasidoneThe metabolism of Nilvadipine can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take without regard to meals
References
Synthesis Reference

Minoru Nakano, Toshinobu Uemura, Shinichi Morizane, Kiyoshi Okuda, Keiko Nakata, “Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine.” U.S. Patent US5340591, issued March, 1985.

US5340591
General ReferencesNot Available
External Links
ATC CodesC08CA10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9377
Blood Brain Barrier-0.9749
Caco-2 permeable+0.6864
P-glycoprotein substrateSubstrate0.5516
P-glycoprotein inhibitor IInhibitor0.915
P-glycoprotein inhibitor IIInhibitor0.9125
Renal organic cation transporterNon-inhibitor0.9071
CYP450 2C9 substrateNon-substrate0.8306
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateSubstrate0.7268
CYP450 1A2 substrateInhibitor0.7753
CYP450 2C9 inhibitorInhibitor0.5318
CYP450 2D6 inhibitorNon-inhibitor0.9291
CYP450 2C19 inhibitorInhibitor0.6042
CYP450 3A4 inhibitorInhibitor0.6375
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8599
Ames testNon AMES toxic0.6114
CarcinogenicityNon-carcinogens0.5194
BiodegradationNot ready biodegradable0.995
Rat acute toxicity2.5335 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7842
hERG inhibition (predictor II)Non-inhibitor0.8944
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0124 mg/mLALOGPS
logP2.97ALOGPS
logP2.24ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)-0.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area134.24 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity101.8 m3·mol-1ChemAxon
Polarizability37.54 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Rosenthal J: Nilvadipine: profile of a new calcium antagonist. An overview. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S92-107. [PubMed:7898101 ]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  3. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Li GR, Deng XL, Sun H, Chung SS, Tse HF, Lau CP: Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells. 2006 Jun;24(6):1519-28. Epub 2006 Feb 16. [PubMed:16484345 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Araie M, Mayama C: Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8. [PubMed:20933604 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Rosenthal J: Nilvadipine: profile of a new calcium antagonist. An overview. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S92-107. [PubMed:7898101 ]
  2. Honerjager P, Seibel K: Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist. J Cardiovasc Pharmacol. 1992;20 Suppl 6:S15-21. [PubMed:1283184 ]
  3. Araie M, Mayama C: Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8. [PubMed:20933604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated ion channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity).
Gene Name:
CACNA2D3
Uniprot ID:
Q8IZS8
Molecular Weight:
123010.22 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194 ]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839 ]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509 ]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on May 16, 2010 11:33 / Updated on August 17, 2016 12:24